We tested the hypothesis that combined treatment with melatonin, an anti-oxidant, and exendin-4, an anti-inflammatory agent, was superior to either alone for protecting the kidney from ischemia-reperfusion (IR) injury. Male adult Sprague-Dawley rats (n¼40) were equally divided into group 1 (sham-operated control), group 2 (IR only, IR¼1h/72h), group 3 (IR-exendin-4, 10 mg/kg at 30 min, 24 h, 48 h after IR procedure), group 4 (IR-melatonin, i.p. 50 mg at 30 min, then 20 mg at 6 and 18 h after IR procedure), and group 5 (combined IR-exendin-4-melatonin). All animals were sacrificed by 72 h after IR/sham procedure. The results showed that the kidney injury score, plasma creatinine, and blood urea nitrogen (BUN) levels were highest in group 2 and lowest in group 1, significantly higher in groups 3 and 4 than those in group 5 and significantly higher in group 3 than those in group 4 (all p < 0.001). The protein expressions of inflammatory (toll-like receptor 4, inducible nitric oxide synthase, interleukin-1b), apoptotic (mitochondrial Bax, cleaved caspase-3 and poly(ADP-ribose) polymerase, p53), podocyte integrity (E-cadherin, P-cadherin), and cell survival (phosphatidylinositol-3-kinase/AKT/mammalian target of rapamycin) biomarkers, as well the podocyte dysfunction biomarkers (Wnt1/Wnt4/b-catenin) displayed a pattern identical to that of creatinine level among the five groups (all p < 0.001). Microscopic findings demonstrated that podocyte dysfunction (Wnt1/Wnt4/b-catenin expression) and inflammatory (CD14 and F4/80-positively stained cells) biomarkers exhibited an identical pattern, whereas that of antioxidant (HO-1 þ , NQO-1 þ cells) biomarkers showed an opposite pattern compared to that of creatinine level among the five groups (all p < 0.001). Combined melatonin-exendin-4 therapy offered an additional benefit in protecting the kidney from acute IR injury.
Introduction
Acute kidney injury (AKI), which is common in hospitalized patients, includes a group of clinical syndromes that primarily manifest as a rapid decline in renal function in association with the accumulation of metabolic waste. 1, 2 Previous study has shown that in the U.S. about 17 million hospital admissions a year are complicated by AKI, resulting in additional costs to the health care system of up to $10 billion. 1 Additionally, the incidence of AKI has been reported to rise from approximately 60 to 500 per 100,000 population in the last decade. 3, 4 The aetiology of AKI has been found to be multifactorial. [5] [6] [7] [8] [9] [10] . Acute ischemia-reperfusion (IR) injury of the kidney, in particular, not only is a common cause of AKI, but it also remains a major health care problem with a high rate of in-hospital mortality 7, 8, 11, 12 and increased risk of long-term mortality 8, [13] [14] [15] [16] despite current advances in medical treatment. This situation, therefore, warrants the development of new treatment modalities for improving the kidney function after AKI. [17] [18] [19] The mechanism underlying acute IR injury of organs, including that of the kidney, has been found to be mainly due to the burst of oxidative stress/reactive oxygen species (ROS) [20] [21] [22] and rigorously inflammatory reaction 19 during reperfusion of ischemic tissues. A reduced blood supply causes severe hypoxia, generation of ROS, and oxidative stress as well as microvascular dysfunction 20, 23 and mitochondrial damage 19 which, in turn, elicits more ROS production. Paradoxically, the subsequent reperfusion enhances, rather than alleviates, the damage through activating a vicious cycle of increased production of ROS and oxidative reaction, vigorous inflammatory reaction, complement activation, immune cell infiltration in ischemic tissue, and upregulation of innate and adaptive immune response that elicit cellular apoptosis and death and ultimately organ failure. 1, [18] [19] [20] [21] [22] [23] [24] [25] [26] Accordingly, inhibition of inflammatory reaction and suppression of the generations of pro-inflammatory cytokines and ROS/oxidative stress using pharmaco-modulation may significantly protect the kidney from acute IR injury.
Exendin-4 (Ex4), a glucagon-like peptide-1 (GLP-1) analog, was originally developed as a therapeutic agent for type 2 diabetes mellitus. Interestingly, growing data have shown that exendin-4 therapy has additional beneficial effects other than blood sugar regulation on the protection of tissues and organs from ischemic damage 25, 27 mainly through its antioxidative and anti-inflammatory properties. 25, [27] [28] [29] On the other hand, melatonin, an indole mainly secreted from the pineal gland, is a free radical scavenger and anti-inflammatory agent that has been demonstrated to play an essential role in maintaining cell membrane stability and protecting the cell from senescence and death mainly through a reduction in the susceptibility to oxidative stress and free radical damage as well as a suppression of inflammatory reaction. [15] [16] [17] [18] Furthermore, multiple signaling pathways mainly related to the generation of ROS/oxidative stress and inflammatory reaction have been shown to be involved in acute kidney IR injury. 1, [18] [19] [20] [21] [22] [23] [24] [25] [26] Thus, it is rational to hypothesize that combined therapy with melatonin and exendin-4 would be superior to either alone for protecting the kidney from acute IR injury mainly through the suppressions of (1) inflammatory reaction, (2) generation of ROS and oxidative stress, (3) cell apoptosis, and (4) regulating the PI3K/AKT/ mTOR intracellular signaling pathway which plays a central role in the regulation of cell cycle, cell proliferation, survival, and growth in response to extracellular stimulation.
Methods

Ethics
All animal experimental procedures were approved by the Institute of Animal Care and Use Committee at Kaohsiung Chang Gung Memorial Hospital (Affidavit of Approval of Animal Use Protocol No. 2011053001) and performed in accordance with the Guide for the Care and Use of Laboratory Animals (The Eighth Edition of the Guide for the Care and Use of Laboratory Animals [NRC 2011]).
Animals were housed in an Association for Assessment and Accreditation of Laboratory Animal Care Internationalapproved animal facility in our hospital with controlled temperature and light cycle (24 C and 12/12 light cycle).
Procedure and protocol of kidney IR and treatment strategy
Pathogen-free, adult male Sprague-Dawley (SD) rats (n ¼ 40) weighing 320-350 g (Charles River Technology, BioLASCO Taiwan Co. Ltd, Taiwan) were equally categorized into five groups (i.e. n¼8/each group): sham control (SC) (receiving laparotomy plus intraperitoneal administration of 3.0 mL normal saline at 30 min and days 1-3 after IR procedure), IR (receiving similar treatment as SC except for IR of both kidneys), IR þ exendin-4 ([IR þ Ex4], subcutaneous administration of exendin-4 10 mg/kg at 30 minute and at days 1-3 after IR procedure), IR þ melatonin ([IR-Mel], 20 mg/kg at 0.5 h after IR and 50 mg/kg at 6 and 18 h after IR procedure), and IR þ Ex4 þ Mel.
The procedure and protocol of acute kidney IR procedure have been described in detail in our previous reports. 18, 25, 26 Briefly, animals in groups 1-5 were anesthetized by inhalational 2.0% isoflurane, placed in a supine position on a warming pad at 37 C for midline laparotomies. The SC received laparotomy only, while acute IR injury of both kidneys was induced in all animals in groups 2-5 by clamping the renal pedicles for 1 h using non-traumatic vascular clips. The animals in each group were euthanized and kidney specimens were collected for individual study by day 3 after the IR procedure.
The dosage and time points of melatonin administration to the animals at 30 min and 6 and 18 h after acute kidney IR were based on our recent reports. 19, 30 Similarly, the dosage of exendin-4 administration was based on our recent reports with minimal modifications. 25, 27 Examination of circulating levels of creatinine and blood urea nitrogen (BUN), and collection of 24 h urine for the ratio of urine protein to creatinine at 72 h after acute kidney IR injury Blood samples were collected from all animals in each group for measuring the changes in serum creatinine and BUN levels at 72 h after IR procedure.
For the collection of 24 h urine for individual study, each animal was put into a metabolic cage (DXL-D, space: 19 cm Â 29 cm Â 55 cm, Suzhou Fengshi Laboratory Animal Equipment Co. Ltd, Mainland China) for 24 h with free access to food and water. Urine in 24 h was collected in all animals at from 48 to 72 h after the IR procedure for determining the daily urine volume and the ratio of urine protein to urine creatinine.
Qualitative analysis of kidney injury scores at 72 h after IR procedure
Histopathology scoring of kidney injury was assessed in a blinded fashion as we previously reported. 18, 19, 25, 26 Briefly, the kidney specimens from all animals were fixed in 10% buffered formalin, embedded in paraffin, sectioned at 5 mm, and stained with hematoxylin and eosin (H&E) for light microscopy. The scoring system reflecting the grading of tubular necrosis, loss of brush border, cast formation, and tubular dilatation in 10 randomly chosen, non-overlapping fields (200x) was as follows: 0 (none), 1 ( 10%), 2 (11-25%), 3 (26-45%), 4 (46-75%), and 5 (!76%).
Western blot analysis
The procedure and protocol for Western blot analysis were based on our recent reports. 18, 19, [25] [26] [27] Briefly, equal amounts (50 mg) of protein extracts were loaded and separated by SDS-PAGE using acrylamide gradients. After electrophoresis, the separated proteins were transferred electrophoretically to a polyvinylidene difluoride membrane (GE Healthcare Bio-Sciences, Marlborough, MA, USA). Nonspecific sites were blocked by incubation of the membrane in blocking buffer (5% nonfat dry milk in T-TBS [TBS containing 0.05% Tween 20]) overnight. The membranes were incubated with the indicated primary antibodies ( Signaling, Danvers, MA, USA) was used as a secondary antibody for 1 h incubation at room temperature. The washing procedure was repeated eight times within 1 h. Immunoreactive bands were visualized by enhanced chemiluminescence (ECL; Thermo Scientific Pierce, Waltham, MA, USA) and exposed to Super RX film (FUJIFILM Super RX, Minato-ku, Tokyo, Japan). For the purpose of quantification, ECL signals were digitized using Labwork software (UVP, Waltham, MA, USA).
Immunohistochemical (IHC) and immunofluorescent (IF) staining
The procedure and protocol of IF staining have been described in detail in our previous reports. 18, 19, 25, 26, 30 
Assessment of oxidative stress
The procedure and protocol for evaluating the protein expression of oxidative stress have been described in detail in our previous reports. 27, 30, 31 The Oxyblot Oxidized Protein Detection Kit was purchased from Chemicon, Billerica, MA, USA (S7150). DNPH derivatization was carried out on 6 mg of protein for 15 min according to the manufacturer's instructions. One-dimensional electrophoresis was carried out on 12% SDS/polyacrylamide gel after DNPH derivatization. Proteins were transferred to nitrocellulose membranes that were then incubated in the primary antibody solution (anti-DNP 1: 150) for 2 h, followed by incubation in secondary antibody solution (1:300) for 1 h at room temperature. The washing procedure was repeated eight times within 40 min. Immunoreactive bands were visualized by ECL (Thermo Scientific Pierce, Waltham, MA, USA) which was then exposed to Super RX film (FUJIFILM Super RX, Minato-ku, Tokyo, Japan). For quantification, ECL signals were digitized using Labwork software (UVP, Waltham, MA, USA). For oxyblot protein analysis, a standard control was loaded on each gel.
In vitro study for determining the effect of TNF-a on stimulating the expressions of PI3K/AKT/mTOR signaling pathway
The normal rat kidney epithelial cells (NRK, ATCC CRL-6509) were utilized in the in vitro study for assessing the effect of TNF-a (i.e. an indicator of inflammatory mediator) on activating the PI3K/AKT/mTOR signaling pathway that mimicked the setting of acute kidney IR injury mainly through inflammatory reaction. In this in vitro study, we first performed time courses of PI3K/AKT/ mTOR expressions (see Figure 1 ) undergoing the stimulation of TNF-a (10 ng/mL) (i.e. co-culture with the cells). In this way, we found that 30 min after TNF-a stimulation was the first time point for the peak-level expressions of PI3K/AKT/mTOR signaling. Accordingly, this time interval was utilized for assessing the impact of Mel-Ex4 therapy on regulating the expressions of PI3K/AKT/ mTOR signaling undergoing the TNF-a treatment ( Figure 1 ).
Statistical analysis
Quantitative data are expressed as mean AE SD. Statistical analysis was adequately performed by ANOVA, followed by Bonferroni multiple-comparison post hoc test. SAS statistical software for Windows version 8.2 (SAS institute, Cary, NC) was utilized. A probability value < 0.05 was considered statistically significant.
Results
Time courses of PI3K/AKT/mTOR expressions with respect to TNF-a stimulation and the impact of Ex4-Mel treatment on regulating PI3K/AKT/mTOR signaling pathway in in vitro study ( Figure 1 )
The western blot results (Figure 1(a) ) showed that as compared with baseline (i.e. at 0 min) the protein expression of p-AKT and PI3K were unregulated at the time intervals of 30 min, 3, 12, and 24 h, respectively. On the other hand, the upregulation of mTOR at these time intervals was not obvious. Additionally, two peak levels of p-AKT protein were identified at 30 min and 12 h, respectively.
By the time point of 30 min after TNF-a treatment, the protein of p-AKT (0.122 AE 0.007 versus 0.824 AE 0.075 versus 0.594 AE 0.054 versus 0.658 AE 0.067 versus 0.316 AE 0.049, p < 0.01) was lowest in control group and highest in TNFa-treated group, and significantly higher in TNF-a-Mel and TNF-a-Ex4 groups than in TNF-a-Ex4-Mel group, but it showed no difference between TNF-a-Mel group and TNF-a-Ex4 group (Figure 1(b) ).
Additionally, by the time point of 30 min after TNF-a treatment, the protein expression of PI3K (0.124 AE 0.016 versus 0.269 AE 0.025 vs. 0.186 AE 0.012 vs. 0.237 AE 0.003 vs. 0.171 AE 0.017, p < 0.01) showed an identical pattern of p-AKT among the five groups (Figure 1(c) ).
Furthermore, by the time point of 30 min after TNF-a treatment, the protein expression of mTOR (0.076 AE 0.008 vs. 0.125 AE 0.011 vs. 0.104 AE 0.014 vs. 0.111 AE 0.012 vs. 0.103 AE 0.009, p < 0.01) was significantly lower in control group than in other four groups, and significantly higher in TNF-a-treated group than in TNF-a-Mel, TNF-a-Ex4, and TNF-a-Ex4-Mel groups, but it showed no difference among the later three groups (Figure 1(d) ).
Serum level of creatinine and BUN, urine amount, and the ratio of urine protein to creatinine at 72 h after IR procedure ( Figure 2 ) dysfunction, were highest in the IR only group and lowest in SC, and significantly higher in IR-Ex4 and IR-Mel groups than those in the IR-Ex4-Mel group, but there was no notable difference in the two parameters between IR-Ex4 and IR-Mel groups.
The 24 h urine volume by 72 h was highest in the IR-Ex4-Mel group and lowest in IR only, significantly higher in IR-Ex4 and IR-Mel groups than that in SC, but it showed no difference between IR-Ex4 and IR-Mel animals (28.663 AE 2.315 vs. 22.063 AE 3.077 vs. 36.600 AE 5.381 vs. 38.038 AE 5.015 vs. 50.025 AE 2.816, p < 0.0001). Additionally, the ratio of urine protein to urine creatinine, an indicator of integrity of renal function, expressed an identical pattern compared to that of creatinine level among the five groups (0.864 AE 0.068 vs. 1.802 AE 0.122 vs. 1.451 AE 0.071 vs. 1.434 AE 0.057 vs. 1.183 AE 0.064, p < 0.001). These findings imply that combined melatonin-exendin-4 treatment offered an additional benefit of protecting the kidney from acute IR injury.
Histopathological findings of kidney parenchymal injury at 72 h after IR procedure ( Figure 3 )
H&E staining showed that the kidney injury score was highest in IR only animals and lowest in SC, significantly higher in IR-Ex4 and IR-Mel groups than that in 0.175 AE 0.020, p < 0.0001), a molecule with an important role to play in apoptosis, exhibited a pattern identical to that of PI3K/AKT/mTOR among the five groups. We suggest that an upregulation of these parameters in kidney parenchyma is the result of IR injury. Elevated levels of 1.576 AE 0.120, p < 0.001), three indicators of oxidative stress, were highest in IR group and lowest in the SC, and significantly higher in IR-Ex4 and IR-Mel groups than those in IR-Ex4-Mel group, and significantly higher in IR-Mel group than those in IR-Ex4 group.
The protein expressions of markers for podocyte integrity and renal tubular injury at 72 h after IR procedure ( Figure 6 IF staining for identification of inflammatory cell infiltration and the expressions of Wnt1 and Wnt4 in kidney parenchyma at 72 h after IR procedure (Figures 7 and 8 13 .186 AE 1.189 vs. 6.661 AE 0.0460, p < 0.0001) cells (number of CD14 þ / high-power field), two indicators of inflammation, were highest in IR group and lowest in SC, significantly higher in IR-Ex4 and IR-Mel groups than those in IR-Ex4-Mel group, and significantly higher in IR-Mel group than those in IR-Ex4 groups (Figure 7) .
On the other hand, the expression pattern of Wnt1 other groups with different symbols (y, z, §, ô), p < 0.0001. All statistical analyses were performed by one-way ANOVA, followed by Bonferroni multiple comparison post hoc test (n¼8 for each group). Symbols (*, y, z, §, ô) indicate significance (at 0.05 level). Ex4: exendin-4; IR: ischemia-reperfusion; Mel: melatonin; SC: sham control of renal tubular injury, was identical to that of the expressions of CD14 þ and F4/80 þ cells around the renal tubules among the five groups (Figure 8) .
Apoptotic nuclei and b-catenin expression in kidney parenchyma at 72 h after IR procedure (Figure 9 )
IF microscopy revealed that the expression of b-catenin (1.333 AE 0.0001 vs. 4.750 AE 0.083 vs.
2.833 AE 0.215 vs.4.000 AE 0.136 vs. 1.917 AE 0.210, p < 0.0001) in renal tubules was highest in IR only animals and lowest in SC, significantly higher in IR-Ex4 and IR-Mel groups than that in IR-Ex4-Mel group, and significantly in IR-Mel group than that in IR-Ex4 group. Additionally, TUNEL assay (2.2 AE 0.5 vs. 52.9 AE 1.8 vs. 15.3 AE 1.1 vs.31.6 AE 0.6 vs. 7.8 AE 1.0, p < 0.0001) identified an identical pattern between the number of apoptotic nuclei and b-catenin expression in kidney parenchyma among the five groups.
IF staining for identification of antioxidant and GLP-1 receptor expression in kidney parenchyma at 72 h after IR procedure (Figures 10 and 11) IF microscopy showed that the numbers of positively stained HO- (Figure 10) .
The protein expression of GLP-1R (0.041 AE 0.006 vs. 0.130 AE 0.007 vs. 0.302 AE 0.022 vs. 0.261 AE 0.018 vs. 0.484 AE 0.029, p < 0.0001) in kidney parenchyma was highest in IR-Ex4-Mel group and lowest in SC, significantly higher in IR-Ex4 and IR-Mel groups than in IR group, and significantly higher in IR-Ex4 group than in IR-Mel ( Figure 11 ). Furthermore, IHC staining demonstrated that the expression of GLP-1R (1.056 AE 0.06 vs. 1.611 AE 0.125 vs.
2.722 AE 0.125 vs. 2.111 AE 0.172 vs. 3.389 AE 0.245, p < 0.0001) in kidney was similar to that of its protein expression among the five groups (Figure 11 ).
Discussion
This study, which investigated the impact of exendin-4-melatonin treatment on acute kidney IR injury, yielded several striking implications. First, both Wnt/b-catenin and PIK3/ AKT/mTOR signaling pathways were turned on in the setting of acute kidney IR injury. Second, the inflammatory reaction was markedly augmented after acute kidney IR injury. Third, the markedly increased expressions of apoptotic biomarkers in kidney parenchyma after IR procedure could possibly explain substantially elevated kidney injury score and significantly deteriorated renal function in IR animals as compared with those in the SC group. Finally, these molecular perturbations were significantly reversed after exendin-4 or melatonin treatment and further significantly reversed following combined exendin-4-melatonin treatment.
One important finding in the present study is that the circulating levels of creatinine and BUN (i.e. the functional assay) were remarkably increased in IR animals compared to that of the SC group at 72 h after IR procedure. Additionally, the kidney injury score was notably increased in IR animals as compared with those in SC animals. These findings suggested that the AKI model was successfully created and ready for individual study. The most important finding is that the deteriorated renal function and kidney injury score were significantly reversed in IR animals by either melatonin or exendin-4 therapy and further significantly reversed after the combined exendin-4-melatonin treatment. Interestingly, the results of our present study were consistent with those of our previous investigation that demonstrated an additional benefit of combined therapy with exendin-4 and sitagliptin of protecting the kidney from IR injury, 25 although the treatment strategies are different between the two studies. IR injury has been previously shown to elicit vigorous inflammatory response. 18, 19, [25] [26] [27] 31, 32 The essential finding in the present study is that the inflammatory reactions were substantially stronger in IR animals than those in SC animals not only at the protein level but also at the cellular level. Our findings corroborated those of the previous studies. 18, 19, [25] [26] [27] 31, 33 Moreover, inflammatory reaction switched on by IR injury in organs with the generation of ROS and oxidative stress and immune response would, in turn, further contribute to organ dysfunction. 27 Intriguingly, the present study further revealed an association between an increased level of inflammatory and ROS/ oxidative stress parameters and enhancement of kidney injury score and the deterioration of renal function in IR animals. Therefore, the findings of the present study reinforced those of previous study. 34 Of importance is that the expressions of inflammatory and ROS/oxidative stress parameters were remarkably reduced through melatonin administration, further remarkably reduced by exendin-4 treatment, and more further significantly reduced by the combined exendin-4-melatonin treatment. Our findings, again, support that combined Ex4-Mel treatment is superior to either alone for protecting the kidney from acute IR injury.
The Wnt/b-catenin signaling pathway has been identified in a wide variety of chronic kidney diseases (CKD). 35, 36 Besides, Wnt/b-catenin signaling has been reported to promote proteinuria, cell apoptosis, and renal interstitial fibrosis. 37, 38 A principal finding in the present study is that the protein and cellular expressions of Wnt1, Wnt4, and b-catenin were significantly increased in IR animals than those in SC animals. Accordingly, our findings, in addition to reinforcing those of previous studies, [35] [36] [37] [38] could at least in part explain the substantially increased apoptosis at cellular and protein levels in IR animals as compared with those in the SC group. Importantly, combined Ex4-Mel treatment was superior to either alone for suppressing the Wnt/b-catenin signaling pathway and reducing the expressions of apoptotic parameters at both protein and cellular levels.
It is well known that PI3K/AKT/mTOR is an intracellular signaling pathway which plays a central role in the regulation of cell cycle, cell proliferation, survival, and growth in response to extracellular signals. 33, 39 Another principal finding in the present study is that the PI3K/AKT/mTOR signaling pathway in both in vitro and in vivo studies was remarkably upregulated in TNF-a treatment and in IR animal and was significantly suppressed after exendin-4melatonin treatment. We proposed that the upregulation of PI3K/AKT/mTOR signaling in the IR setting is a tissue/ organ intrinsic response to IR stimulation (i.e. the more severe the IR damage, the more vigorous is the response). This may explain the highest expression of apoptotic parameters in IR animals without treatment compared with that in the other groups.
An interesting finding in the present study is the remarkably higher GLP-1R expression in IR-Ex4 and IR-Ex4-Mel groups than those in the other groups on Western blot and IHC staining. Our previous study also showed that, in the setting of acute kidney IR injury, this biomarker was notably upregulated after exendin-4 treatment. 25 Accordingly, the finding of the present study strengthened that of our previous study. 25 Another intriguing finding is that the expressions of HO-1 and NQO 1 antioxidants at cellular level were progressively increased from SC to IR-Ex4-Mel groups. This finding suggests that an increase in antioxidant expressions is an intrinsic capacity of cells/tissues in response to ischemic stress and could be augmented through combination of melatonin and exendin-4 treatment. The findings in the present study are consistent with those of our previous studies that demonstrated this phenomenon in other settings of organ IR injury. 19, 25, 27, 32 
Study limitations
This study has limitations. First, although the short-term results of the present study were promising, the long-term outcome of combined exendin-4-melatonin on protecting kidney from acute IR injury remains uncertain. Second, although extensive work was done in this study, a novel mechanistic signaling pathway involved in kidney injury in the setting of IR has not been identified.
In conclusion, combined melatonin-exendin-4 therapy effectively attenuated the kidney from IR injury. Our findings highlight the potential clinical impact of this therapeutic regimen on patients with AKI, especially in the IR setting.
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